Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AVA 4746

Drug Profile

AVA 4746

Alternative Names: AVA4746; TBC 4746

Latest Information Update: 02 Feb 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Encysive Pharmaceuticals
  • Developer Aviara Pharmaceuticals; Encysive Pharmaceuticals; Pfizer; Schering-Plough
  • Class Small molecules
  • Mechanism of Action Integrin alpha4beta1 antagonists; Vascular cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Stem cell mobilisation
  • Discontinued Asthma; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 17 Jan 2017 Preclinical trials in Stem cell mobilisation in USA (unspecified route)
  • 03 Dec 2016 Pharmacodynamics data from preclinical studies in Acute lymphoblastic leukemia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 11 Jun 2008 Encysive Pharmaceuticals has been acquired by Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top